Telix Precision Medicine Announces AlFluor Radiochemistry Platform

20 Jun 2025

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces it has launched a novel PET [1] radiochemistry solution based on ^{18}F-aluminium fluoride (AlF), named AlFluor™.

The AlFluor™ platform technology enables flexible radiolabeling of PSMA[2] with either AlF or gallium-68 (^{68}Ga). It also has the potential to be used with ligands targeting NETs[3] and FAP[4], as well as other novel imaging agents under development by Telix and its strategic partners. Developed to combine the imaging benefits of ^{18}F with the convenience of ^{68}Ga kit-based workflows, the AlFluor™ platform supports both centralized cyclotron manufacturing and distributed "shake-and-inject" kit production. This flexibility allows a complementary product with the same targeting agent to be labeled with either isotope, catering to clinical setting or physician preference.

As part of AlFluor's development, Telix has signed a strategic agreement with University Hospital Ghent and Ghent University for a novel [^{18}F]AlF-PSMA-11 targeting agent. The agreement includes a comprehensive chemistry, manufacturing and controls (CMC) package suitable for the preparation of a Drug Master File (DMF), and provides exclusive access to [^{18}F]AlF-PSMA-11 clinical safety and efficacy data, including a Phase 3 trial in 96 prostate cancer patients, where PSMA-11 (gozetotide) was labeled interchangeably with ^{18}F and ^{68}Ga.

The trial demonstrated diagnostic performance comparable to commercial ^{68}Ga-labeled PSMA-11 agents such as Illuccix® and Gozellix®, both known to deliver high specificity (~90%) for metastatic detection at initial staging[5]. [^{18}F]AlF-PSMA-11 has also demonstrated favorable biodistribution, high tumor-to-background ratios, and low off-target uptake in multiple studies[6]. Telix has commenced engagement with regulators to determine the pathway to approval for [^{18}F]AlF-PSMA-11.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, "Telix's goal is to expand the utilization of PSMA-PET imaging through clinical leadership and novel, flexible product deployment that enables physician choice. AlFluor™ is an example of innovation that meets the evolving needs of physicians and their patients. The addition of this advanced-stage technology and product candidate aligns with our strategy to offer the broadest choice of PSMA-PET imaging agents, with the service, flexibility and reliability that define the Telix customer experience."

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (^{68}Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, has been approved in multiple countries globally. Gozellix® (kit for the preparation of gallium-68 (^{68}Ga) gozetotide injection) has been approved by the U.S. FDA[7].

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)

Annie Kasparian
Telix Pharmaceuticals Limited
Director Investor Relations and Corporate Communications
Email: annie.kasparian@telixpharma.com

Telix Media Relations (U.S.)

Eliza Schleifstein
ES Media Relations
Email: eliza@schleifsteinpr.com
Phone: 917-763-8106

are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

---

[1] Positron emission tomography.

[2] Prostate-specific membrane antigen.

[3] Neuroendocrine tumors.

[4] Fibroblast activation protein.

[5] PSMA-PreRP clinical study. ClinicalTrials.gov ID: NCT02919111.

[6] Piron et al. *Sci Rep.* 2021; Malik et al. *EJNMMI Res*. 2020; Boschi et al. *EJNMMI Res*. 2020.

[7] Telix ASX disclosure 21 March 2025.